Flare Therapeutics
- Founded: 2021
- Location: Cambridge, MA
- Employee range: 11 - 50
- Clinical stage: Clin0
- Therapy area: Advanced urothelial cancer, solid tumors
- Drug types: ONC
- Lead product: FX-909
- Product link: https://www.flaretx.com/pipeline/
- Funding: $123M B Mar 2023; $82M A May 2021
- Investors: Pfizer Ventures, GordonMD Global Investments, Boxer Capital, Eventide Asset Management, Third Rock Ventures, Novartis, Eli Lilly
flaretx.com linkedin.com job board
Short description:
Therapeutics Targeting Transcription Factors
Drug notes:
5 additional undisclosed programs RD oncology
Long description:
Flare Therapeutics is targeting transcription factors to identify therapeutics for cancer treatment. Transcription factors (TFs) bind DNA and control gene expression, which dictates the functional output of a cell. Due to their importance, mutations in TFs are common causes of cancer, yet this protein class has remained elusive for drug discovery. Flare is changing this by designing small molecules that target the switch site of TFs to regain transcriptional control. Switch sites reflect the cooperative nature of TF domains and offer a new druggable pocket to control activity. With this information, Flare is developing a differentiated pipeline of drug programs to target the central genetic drivers of cancer and other diseases.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com